← MARAVAI LIFESCIENCES HOLDINGS, INC.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $143.1m |
$284.1m
+98.48%
|
$799.2m
+181.33%
|
$883.0m
+10.48%
|
$288.9m
-67.28%
|
$259.2m
-10.30%
|
$185.7m
-28.34%
|
$208.8m
+12.40%
|
|
| Cost of revenue | $66.8m |
$79.6m
+19.15%
|
$140.6m
+76.48%
|
$169.0m
+20.20%
|
$148.7m
-11.96%
|
$150.9m
+1.43%
|
$151.8m
+0.58%
|
$135.9m
-10.43%
|
|
| Gross profit | $76.3m |
$204.4m
+167.99%
|
$658.7m
+222.17%
|
$714.0m
+8.41%
|
$140.2m
-80.37%
|
$108.3m
-22.75%
|
$34.0m
-68.62%
|
$72.8m
+114.32%
|
|
| Research and development | $3.6m | $9.3m | $15.2m | $18.4m | $17.3m | $19.2m | $17.4m | $15.2m | |
| Selling, general and administrative | $48.4m | $94.2m | $100.1m | $129.3m | $151.4m | $161.8m | $145.1m | $128.0m | |
| Restructuring | — | — | $0 | $0 | $6.5m | ($1.2m) | $17.8m | $20.9m | |
| Total operating expenses | $119.2m | $164.2m | $244.6m | $308.8m | $320.6m | $494.8m | $249.3m | $279.2m | |
| Loss from operations | $24.0m |
$119.9m
+399.84%
|
$554.6m
+362.58%
|
$574.2m
+3.53%
|
($31.6m)
-105.51%
|
($235.6m)
-644.49%
|
($215.3m)
+8.64%
|
— | |
| Interest expense | ($30.0m) | ($30.7m) | ($30.3m) | ($20.4m) | ($45.9m) | ($47.7m) | ($27.0m) | $24.0m | |
| Interest income | — | $0 | $0 | $2.3m | $27.7m | $27.4m | $11.4m | $8.2m | |
| Other expense | $118k | $126k | $279k | ($358k) | ($1.3m) | ($2.3m) | ($4.2m) | — | |
| (Loss) income before income taxes | ($5.9m) | $81.7m | $530.8m | $551.5m | $617.7m | ($261.5m) | ($235.0m) | — | |
| Income tax (benefit) expense | ($652k) | $2.9m | $61.5m | $60.8m | $756.1m | ($1.9m) | ($4.2m) | — | |
| Net loss | ($5.2m) | $78.8m | $469.2m | $490.7m | ($138.4m) | ($259.6m) | ($230.8m) | — | |
| Net loss attributable to non-controlling interests | ($731k) | ($10.2m) | $287.2m | $270.5m | ($19.3m) | ($114.8m) | ($100.0m) | — | |
| Net loss attributable to Maravai LifeSciences Holdings, Inc. | ($4.5m) | $89.0m | $182.0m | $220.2m | ($119.0m) | ($144.8m) | ($130.8m) | — | |
| Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share) | ($0) | $7 | $2 | $2 | ($1) | ($1) | ($1) | — | |
| Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share) | ($0) | $2 | $2 | $2 | ($1) | ($1) | ($1) | — | |
| Weighted average Class A common shares outstanding—basic (in shares) | 253.9m | 10.4m | 114.8m | 131.5m | 131.9m | 137.9m | 144.4m | — | |
| Weighted average Class A common shares outstanding - diluted (in shares) | 253.9m | 28.9m | 257.8m | 255.3m | 131.9m | 137.9m | 144.4m | — | |
| Change in estimated fair value of contingent consideration | $322k | $0 | $0 | ($7.8m) | ($3.3m) | ($2.0m) | $200k | — | |
| Impairment of goodwill and long-lived assets | — | — | — | — | $0 | $166.2m | $68.7m | — | |
| Loss on extinguishment of debt | $0 | ($7.6m) | $0 | ($208k) | $0 | ($3.2m) | $0 | — | |
| Change in payable to related parties pursuant to the Tax Receivable Agreement | $0 | $0 | $6.1m | ($4.1m) | $668.9m | ($40k) | $0 | — |